Cargando…

Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis

Detalles Bibliográficos
Autores principales:	Ribaldone, Davide Giuseppe, Saracco, Giorgio, Pellicano, Rinaldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Dermatologia 2017
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595620/ https://www.ncbi.nlm.nih.gov/pubmed/28954122 http://dx.doi.org/10.1590/abd1806-4841.2017112

Ejemplares similares

Response to: Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2016)

Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis - Reply
por: Mesquita, Priscila Miranda Diogo, et al.
Publicado: (2017)

Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Helicobacter pylori eradication: the relevance of a periodic update
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Comment on “Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Relationship of Helicobacter pylori seroprevalence with the occurrence and severity of psoriasis
por: Mesquita, Priscila Miranda Diogo, et al.
Publicado: (2017)

Strategies for Helicobacter pylori eradication in the year 2020
por: Pellicano, Rinaldo, et al.
Publicado: (2020)

A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Finally, it is Bismuth's Time
por: Ribaldone, Davide G., et al.
Publicado: (2017)

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2018)

Comment on “Factors Associated with Recurrent Ulcers in Patients with Gastric Surgery after More Than 15 Years: A Cross-Sectional Single-Center Study”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2018)

Helicobacter pylori and Respiratory Diseases: 2021 Update
por: Durazzo, Marilena, et al.
Publicado: (2021)

Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Response to: Reply on “Renewed Helicobacter pylori Management and Therapy in 2015”
por: Fagoonee, Sharmila, et al.
Publicado: (2016)

Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520–525
por: Eshraghian, Ahad, et al.
Publicado: (2013)

Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

Indication to Colectomy in the Hands of the Academic Gastroenterologist Versus the Surgeon: Old Giant Combat While Modern “Precision Medicine” Is Timidly Waving Hand to Offer Possible Help
por: Clemente Actis, Giovanni, et al.
Publicado: (2023)

Infections with Helicobacter pylori and challenges encountered in Africa
por: Smith, Stella, et al.
Publicado: (2019)

Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Düzenli, Tolga, et al.
Publicado: (2023)

Is there a low prevalence of Helicobacter pylori infection in Jordanian patients with gastric cancer?
por: Pellicano, Rinaldo
Publicado: (2017)

Comments regarding use of rifabutin for Helicobacter pylori eradication
por: Graham, David Y.
Publicado: (2021)

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis
por: Carli, Edoardo, et al.
Publicado: (2020)

One or Two Weeks of Treatment with Helicobacter pylori “Standard” Triple Therapy in the Year 2015?
por: Pellicano, Rinaldo, et al.
Publicado: (2015)

Which should be the first-line treatment for Helicobacter pylori in Colombia? A lesson from a recent study
por: Pellicano, Rinaldo
Publicado: (2019)

Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity (“lymphocytic enterocolitis”)?
por: Bonagura, Gabriele Antonio, et al.
Publicado: (2016)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Inflammation in gastrointestinal disorders: prevalent socioeconomic factors
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Relationship between Helicobacter pylori infection and psoriasis
por: Azizzadeh, Maryam, et al.
Publicado: (2014)

Seroprevalence of Helicobacter pylori Infection in Korean Health Personnel
por: Kim, Hyun Young, et al.
Publicado: (2013)

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

History of Inflammatory Bowel Diseases
por: Actis, Giovanni Clemente, et al.
Publicado: (2019)

The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

Seroprevalence of Helicobacter pylori among children in Sana’a, Yemen
por: Al-Shamahy, Hassan A.
Publicado: (2005)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Kashani, Negin, et al.
Publicado: (2018)

Comment “Asymptomatic small intestinal ulcerative lesions: Obesity and Helicobacter pylori are likely to be risk factors”
por: Wang, Wei, et al.
Publicado: (2022)

Role of concomitant therapy for Helicobacter pylori eradication: A technical note
por: Losurdo, Giuseppe, et al.
Publicado: (2016)

Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Sue, Soichiro, et al.
Publicado: (2018)

RE: Comment On: Vonoprazan on the Eradication of Helicobacter pylori Infection
por: Huang, Jiaming, et al.
Publicado: (2023)

Helicobacter pylori and Immunocompromised Children
por: Nutpho, Prakaimuk, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_uh98ua80iagcgdk7ha1opglhsq